Search / Trial NCT00002369

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Launched by BRISTOL-MYERS SQUIBB · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Drug Therapy, Combination Zidovudine Stavudine Hiv Protease Inhibitors Cd4 Lymphocyte Count Lamivudine Indinavir Reverse Transcriptase Inhibitors Anti Hiv Agents Viral Load

ClinConnect Summary

100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir).

Patients will be treated for 48 weeks.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • Documented HIV infection.
  • CD4 cell count of 200 - 700 cells/mm3.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • AIDS defining condition within 1 month of study entry.
  • Prior Medication:
  • Excluded:
  • Patients with any history of antiretroviral therapy treatment.

About Bristol Myers Squibb

Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.

Locations

Birmingham, Alabama, United States

St Louis, Missouri, United States

Tampa, Florida, United States

Ponce, , Puerto Rico

Santurce, , Puerto Rico

Brookline, Massachusetts, United States

Fort Lauderdale, Florida, United States

Atlanta, Georgia, United States

New Orleans, Louisiana, United States

Boston, Massachusetts, United States

Austin, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials